West Pharmaceutical Services is a healthcare components manufacturer with a perfect Piotroski F-Score of 9/9, a wide economic moat, four consecutive earnings beats averaging 18.2% above estimates, and strong revenue growth of 21% — though its current price has reached the prior analyst target, making near-term entry timing unfavorable.
Thesis pillars
- Wide Moat Perfect Piotroski→Stable
- Strong Earnings Beat Streak↑Improving
- Revenue Growth Leadership↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
West Pharmaceutical Services, I (WST) Stock Analysis
Oversold Bounce setup
Healthcare · Medical Instruments & Supplies
Wait for pullback to $282.83. At $328.20 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $282.83 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: single-source raw materials; Concentration risk — Geographic: international sales (56.7%).
West Pharmaceutical Services manufactures injectable drug containment and delivery systems—stoppers, seals, syringes, and drug delivery devices—for biologic, generic, and pharmaceutical customers in two segments: Proprietary Products and Contract-Manufactured Products. With... Read more
Wait for pullback to $282.83. At $328.20 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $282.83 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: single-source raw materials; Concentration risk — Geographic: international sales (56.7%). Chart setup: Oversold RSI 30, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 6.2/10, moderate confidence.
Passes 4/7 gates (clean insider activity, earnings proximity 89d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
About West Pharmaceutical Services, I
About West Pharmaceutical Services, I
West Pharmaceutical Services split consolidated net sales 56.7% international and 43.3% domestic in 2025, with manufacturing in North and South America, Europe, and Asia Pacific. The company employed approximately 10,800 people at December 31, 2025—43% in North America, 42% in Europe, and 12% in Asia Pacific. Two reportable segments serve the global injectable drug supply chain: Proprietary Products (elastomers, drug delivery devices, and analytical lab services) and Contract-Manufactured Products (complex device assemblies for pharmaceutical, diagnostic, and medical device customers).
West Pharmaceutical generates revenue by selling primary packaging components—including elastomeric stoppers, seals, polymer syringes, and drug delivery devices—to biologic, generic, and pharmaceutical manufacturers, plus contract manufacturing for surgical, ophthalmic, and other medical device customers. The top ten customers accounted for 47.6% of consolidated net sales in 2025, with one unnamed customer contributing 15.8% ($485.9 million) across both segments. Three primary raw materials—elastomers (synthetic and natural), aluminum, and plastic—are purchased from both open-market and single-source suppliers, with price fluctuations subject to petroleum cost cycles. The company competes with Datwyler and Aptar in Proprietary Products and with Phillips Medisize, Sharp, and PCI Pharma Services in contract manufacturing. Products and services are sold primarily through a dedicated sales force with limited use of contract agents and distributors.
Show full overview
West Pharmaceutical's single-source supplier dependency is structurally embedded: due to FDA and other regulatory quality standards required for injectable packaging components, the company cannot quickly establish replacement sources for many critical inputs. The 10-K discloses that "many components and raw materials are available and/or purchased only from a single supplier," and that a reduction or interruption in supply could have a material adverse effect on operations. This constraint is compounded by manufacturing concentration—certain product lines are produced in only one or a few plants—creating a dual bottleneck scenario if facility and supply disruptions coincide.
See also: Healthcare · Medical Instruments & Supplies
From West Pharmaceutical Services, I's most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-07-26Recent Developments — West Pharmaceutical Services, I
Latest news
- NEWS Insider Selling: West Pharmaceutical Services (NYSE:WST) CAO Sells 896 Shares of Stock - MarketBeat — MarketBeat negative
- NEWS West Pharmaceutical sr. VP Annette Favorite sells $859,753 in shares - Investing.com — Investing.com neutral
- NEWS West Pharmaceutical (WST) Upgraded to Strong Buy: Here's What You Should Know - Yahoo! Finance Canada — Yahoo! Finance Canada positive
- NEWS Are you looking for a top momentum pick? Why West Pharmaceutical Services (WST) is a great choice - MSN — MSN positive
- NEWS Are You Looking for a Top Momentum Pick? Why West Pharmaceutical Services (WST) is a Great Choice - Yahoo Finance — Yahoo Finance positive
Generated 2026-07-26T08:02:05Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertop ten customers48%10-K Item 1: 'Our ten largest customers accounted for 47.6% of our consolidated net sales in 2025'
- LOWCustomerone customer >10% of net sales16%10-K Item 1: 'one of these customers individually accounted for more than 10% of consolidated net sales, at 15.8% or $485.9 million'
- HIGHSuppliersingle-source raw materials10-K Item 1A: 'many components and raw materials are available and/or purchased only from a single supplier'
- HIGHGeographicinternational sales57%10-K Item 1: 'Sales outside of the U.S. accounted for 56.7% of our consolidated net sales in 2025'
Material Events(8-K, last 90d)
- 2026-06-01Item 5.02MEDIUMMichel Lagarde appointed President & CEO effective Aug 31, 2026, succeeding Eric M. Green who announced retirement intent Mar 6, 2026. Lead Independent Director Robert F. Friel named incoming Chair of the Board.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $282.83. At $328.20 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $282.83 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: single-source raw materials; Concentration risk — Geographic: international sales (56.7%). Chart setup: Oversold RSI 30, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $345.64 (+5.3%), stop $260.12 (−26.2%), A.R:R 0.8:1. Score 6.2/10, moderate confidence.
Take-profit target: $345.64 (+5.3% upside). Target $345.64 (+5.3%), stop $260.12 (−26.2%), A.R:R 0.8:1. Stop-loss: $260.12.
Concentration risk — Supplier: single-source raw materials; Concentration risk — Geographic: international sales (56.7%); Thin upside margin: 5.3%.
West Pharmaceutical Services, I trades at a P/E of 45.5 (forward 33.2). TrendMatrix value score: 3.7/10. Verdict: Buy (Wait for Entry).
22 analysts cover WST with a consensus score of 4.3/5. Average price target: $397.
What does West Pharmaceutical Services, I do?West Pharmaceutical Services manufactures injectable drug containment and delivery systems—stoppers, seals, syringes,...
West Pharmaceutical Services manufactures injectable drug containment and delivery systems—stoppers, seals, syringes, and drug delivery devices—for biologic, generic, and pharmaceutical customers in two segments: Proprietary Products and Contract-Manufactured Products. With approximately 10,800 employees, the company generated 56.7% of 2025 net sales internationally, with top-ten customers accounting for 47.6% of consolidated net sales.